- Home
- MIN vs NNNN Comparison
MIN vs NNNN Comparison
Compare MIN & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIN
- NNNN
- Stock Information
- Founded
- MIN 1988
- NNNN 2021
- Country
- MIN United States
- NNNN Germany
- Employees
- MIN N/A
- NNNN N/A
- Industry
- MIN Trusts Except Educational Religious and Charitable
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MIN Finance
- NNNN Health Care
- Exchange
- MIN Nasdaq
- NNNN Nasdaq
- Market Cap
- MIN 306.1M
- NNNN 267.7M
- IPO Year
- MIN N/A
- NNNN 2025
- Fundamental
- Price
- MIN $2.69
- NNNN $6.63
- Analyst Decision
- MIN
- NNNN
- Analyst Count
- MIN 0
- NNNN 0
- Target Price
- MIN N/A
- NNNN N/A
- AVG Volume (30 Days)
- MIN 331.0K
- NNNN 32.8K
- Earning Date
- MIN 01-01-0001
- NNNN 01-01-0001
- Dividend Yield
- MIN 7.31%
- NNNN N/A
- EPS Growth
- MIN N/A
- NNNN N/A
- EPS
- MIN 0.08
- NNNN 0.06
- Revenue
- MIN N/A
- NNNN $8,185,146.00
- Revenue This Year
- MIN N/A
- NNNN N/A
- Revenue Next Year
- MIN N/A
- NNNN N/A
- P/E Ratio
- MIN $33.38
- NNNN $116.38
- Revenue Growth
- MIN N/A
- NNNN 21.95
- 52 Week Low
- MIN $2.52
- NNNN $5.18
- 52 Week High
- MIN $2.88
- NNNN $7.82
- Technical
- Relative Strength Index (RSI)
- MIN 52.32
- NNNN N/A
- Support Level
- MIN $2.65
- NNNN N/A
- Resistance Level
- MIN $2.71
- NNNN N/A
- Average True Range (ATR)
- MIN 0.03
- NNNN 0.00
- MACD
- MIN 0.00
- NNNN 0.00
- Stochastic Oscillator
- MIN 68.75
- NNNN 0.00
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.